CS060380

Phase 2Small molecule

CS060380 is one of 25 small molecule programs targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Active, not recruiting

Non-Alcoholic SteatohepatitisRecruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 2

Recruiting

Competition

Competitive Landscape

24 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

3 2

Estrace

Rifadin

Mounjaro

Cytotec

Aldactone

Trental

VValidus Pharmaceuticals

Approved

1 8

Januvia

ZZydus Therapeutics Inc.

Approved

1 9

Ozempic

Novo Nordisk

Phase 3

4 10

Tricor

JJagotec

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Non-Alcoholic Steatohepatitis

NCT07198386

Q3 2027

Phase 2Active, not recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07466017

Clinical

Trials by Indication[1]

Tics1 trial

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

Completed·CCascade Pharmaceuticals, Inc·Phase 1·NCT06573528·104 enrolled

Non-Alcoholic Steatohepatitis1 trial

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

Recruiting·CCascade Pharmaceuticals, Inc·Phase 2·NCT07198386·120 enrolled

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.

Active, not recruiting·CCascade Pharmaceuticals, Inc·Phase 2·NCT07466017·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CS060380. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CS060380 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CS060380. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cascade Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCascade Pharmaceuticals, Inc

CS060380

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Tics1 trial

Non-Alcoholic Steatohepatitis1 trial

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

References

Drug Info

Quick Facts

Related News